Related Experiment Videos
Other chemotherapy regimens including mitoxantrone and suramin
1Department of Medicine, Princess Margaret Comprehensive Cancer Centre, University of Toronto, Ontario, Canada.
Seminars in Urologic Oncology
|February 1, 1997
Abstract:
This article reviews the role of systemic chemotherapy in the treatment of hormone refractory prostate cancer, with emphasis on the evidence regarding the use of mitoxantrone plus prednisone, suramin, and various investigational regimens. Outcome assessment in this disease has not been uniform; recently evolved measures such as patient-based "palliative" endpoints and prostate-specific antigen responses will be discussed.